Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives $40.75 Consensus Price Target from Analysts

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) has been assigned an average recommendation of “Hold” from the five research firms that are currently covering the company, Marketbeat reports. Three equities research analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $40.75.

Several equities analysts recently commented on COLL shares. Jefferies Financial Group upgraded Collegium Pharmaceutical from a “hold” rating to a “buy” rating and upped their target price for the company from $41.00 to $44.00 in a research note on Friday, June 7th. Needham & Company LLC lowered Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Friday, May 10th. StockNews.com lowered Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, May 1st. Finally, Piper Sandler lowered Collegium Pharmaceutical from an “overweight” rating to a “neutral” rating and set a $39.00 target price for the company. in a research note on Friday, May 10th.

Insider Transactions at Collegium Pharmaceutical

In other news, Director Garen G. Bohlin sold 28,985 shares of the company’s stock in a transaction dated Tuesday, May 14th. The stock was sold at an average price of $32.30, for a total value of $936,215.50. Following the completion of the sale, the director now owns 44,775 shares of the company’s stock, valued at $1,446,232.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, Director Garen G. Bohlin sold 28,985 shares of the stock in a transaction dated Tuesday, May 14th. The stock was sold at an average price of $32.30, for a total value of $936,215.50. Following the completion of the transaction, the director now owns 44,775 shares of the company’s stock, valued at $1,446,232.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Colleen Tupper sold 19,710 shares of the stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $34.21, for a total value of $674,279.10. Following the completion of the transaction, the chief financial officer now directly owns 130,845 shares of the company’s stock, valued at approximately $4,476,207.45. The disclosure for this sale can be found here. Insiders sold 105,502 shares of company stock valued at $3,540,796 over the last quarter. Company insiders own 3.98% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. raised its stake in Collegium Pharmaceutical by 0.8% during the first quarter. Vanguard Group Inc. now owns 2,330,728 shares of the specialty pharmaceutical company’s stock valued at $90,479,000 after buying an additional 17,942 shares in the last quarter. Pacer Advisors Inc. raised its stake in Collegium Pharmaceutical by 68.4% during the fourth quarter. Pacer Advisors Inc. now owns 2,174,718 shares of the specialty pharmaceutical company’s stock valued at $66,938,000 after buying an additional 883,380 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in Collegium Pharmaceutical by 2.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,039,218 shares of the specialty pharmaceutical company’s stock valued at $31,987,000 after buying an additional 29,529 shares in the last quarter. LSV Asset Management raised its stake in Collegium Pharmaceutical by 188.7% during the first quarter. LSV Asset Management now owns 380,551 shares of the specialty pharmaceutical company’s stock valued at $14,773,000 after buying an additional 248,751 shares in the last quarter. Finally, Assenagon Asset Management S.A. raised its stake in Collegium Pharmaceutical by 411.1% during the second quarter. Assenagon Asset Management S.A. now owns 362,137 shares of the specialty pharmaceutical company’s stock valued at $11,661,000 after buying an additional 291,286 shares in the last quarter.

Collegium Pharmaceutical Stock Performance

NASDAQ COLL opened at $36.08 on Monday. Collegium Pharmaceutical has a fifty-two week low of $20.95 and a fifty-two week high of $40.95. The stock has a market cap of $1.18 billion, a price-to-earnings ratio of 15.03 and a beta of 0.93. The business has a fifty day moving average of $32.64 and a 200-day moving average of $34.59. The company has a quick ratio of 1.14, a current ratio of 1.21 and a debt-to-equity ratio of 1.98.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings results on Thursday, May 9th. The specialty pharmaceutical company reported $1.32 earnings per share for the quarter, missing analysts’ consensus estimates of $1.36 by ($0.04). Collegium Pharmaceutical had a return on equity of 104.98% and a net margin of 16.46%. The company had revenue of $144.92 million during the quarter, compared to analyst estimates of $147.04 million. As a group, analysts predict that Collegium Pharmaceutical will post 5.57 earnings per share for the current fiscal year.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.